Advertisement

Related Videos

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Advertisement

Advertisement




Feb
15
Today In Oncology
ASH 2025: Highlights in Relapsed/Refractory Multiple Myeloma
Oncolytic Virus Triggers Immune System Against Glioblastoma Cells
Adjuvant Durvalumab in Resected Early-Stage NSCLC
FDA Approves Labeling Changes to Menopausal Hormone Therapy Products
Young-Onset Pancreatic Cancer Can Alcohol Consumption Raise Risk
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo